Cell Therapeutics, Inc. engages in the development, acquisition, and commercialization of drugs for the treatment of cancer. It is developing Pixuvri, a novel anthracycline derivative for the treatment of hematologic malignancies and solid tumors; OPAXIO, a chemotherapeutic agent that links paclitaxel to a biodegradable polyglutamate for treating ovarian, brain, esophageal, head, and neck cancers; Brostallicin, a synthetic DNA minor groove binding agent; and Bisplatinates, a platinum-based chemotherapy drug to treat various cancers. The company, in collaboration with Chroma Therapeutics, Ltd., is also engaged in developing Tosedostat, an oral aminopeptidase inhibitor. Cell Therapeutics, Inc. was founded in 1991 and is headquartered in Seattle, Washington.
Symbol:
Current Quote
last: 1.16
bid:
ask:
volume: 356400

as of (GMT): 2013-05-17 15:49:39
*Quotes delayed by 20min.
Stock Exchange / Market : NASDAQ
 Off list - 143 consecutive market days. Off list as of 06/02/2008 through 05/17/2013 

3 Month
CTIC 3 Month

6 Month
CTIC 6 Month

1 Year
CTIC 1 Year

Borrow Rates (per share)